Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled

Vinícius Ynoe de Moraes1, Alexandre Rodrigues Marra1, Leandro Luongo Matos1

  • 1Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Insights

Hydroxychloroquine did not significantly reduce mortality in COVID-19 patients. This systematic review found no difference in mortality or serious adverse effects compared to standard care or placebo.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • The COVID-19 pandemic necessitated rapid evaluation of potential treatments.
  • Hydroxychloroquine was investigated for its antiviral and immunomodulatory properties.
  • Evidence on its efficacy and safety in COVID-19 patients remained uncertain.

Approach:

  • A systematic literature review and meta-analysis were conducted.
  • Nine randomized controlled trials involving COVID-19 patients treated with hydroxychloroquine versus placebo or standard care were analyzed.
  • Data on mortality and serious adverse effects were pooled using random-effects models.

Key Points:

  • No significant difference in mortality rates was observed between hydroxychloroquine and control groups (16.7% vs. 18.5%).
  • The rate of serious adverse effects was comparable between groups (3.7% vs. 2.9%).
  • Pooled risk ratios indicated no statistically significant benefit for hydroxychloroquine.

Conclusions:

  • Hydroxychloroquine is not efficacious in reducing mortality for COVID-19 patients.
  • The drug demonstrated no significant safety advantage over standard care or placebo.
  • Further research on hydroxychloroquine for COVID-19 is not warranted based on current evidence.
Abstract

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
303
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
204